Safety and Efficacy of Oral Mifepristone for Cervical Ripening in Single Live Intrauterine Term Unscarred Pregnancies

Abstract

Background: Mifepristone results in cervical ripening in females undergoing pregnancy termination. It causes cervical ripening via blockage of progesterone receptors. Aim: The present study aimed to assess the safety and efficacy of oral Mifepristone for cervical ripening in single-live intrauterine term unscarred pregnancies. Methods: The present study assessed 200 single live-term intrauterine unscarred pregnancies. All were induced using oral mifepristone in 400 mg dose after assessment of BS. A reassessment of BS was done after 24 hours and if needed (in BS 6, subjects were sent to the labor room for oxytocin infusion and ARM, if needed. BS gains after 24 hours, perinatal outcomes, delivery route, and induction to delivery interval were assessed. Results: The mean birth weight in study subjects was 2862.5 ± 85.2 grams. delivery mode was cesarean, outlet forceps delivery, ventouse delivery, and normal delivery in 8.5% (n = 17), 1.55% (n = 3), 3% (n = 6), and 87% (n = 174) study subjects respectively. Asphyxia or need for admission to NICU was reported in 4% (n = 8) of study subjects. re was 0.5% (n = 1) perinatal death in the study. Mean APGAR scores at the 1st and 5th minute were 8 and 9 respectively. Conclusions: Mifepristone is efficacious and safe for inducing labor and cervical ripening in subjects with full-term pregnancy.

Keywords

• cervical ripening
• dinoprostone
• labor augmentation
• labor induction
• oxytocin